Roche DRC Multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability,pharmacokinetics, and pharmacodynamics of RO7200394 following intravitreal administration in patients with nAMD

Administered By

Awarded By

Contributors

Start/End

  • February 1, 2019 - January 8, 2021